Codexis Announces Proposed Public Offering of Common Stock
April 05 2018 - 4:02PM
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company,
today announced that it has commenced an underwritten public
offering of shares of its common stock. All of the shares to be
sold in the offering will be offered by Codexis. In addition,
Codexis intends to grant to the underwriters a 30-day option to
purchase up to an additional 15% of the shares of its common stock
offered in the public offering, on the same terms and conditions.
The offering is subject to market and other conditions, and there
can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
Codexis intends to use the net proceeds from the offering for
general corporate purposes, which may include, among other things,
supporting the development of its product candidates, funding
research and development, increasing its working capital and
capital expenditures.
Jefferies LLC and Cowen and Company, LLC are acting as joint
book-running managers for the proposed offering.
A registration statement relating to these securities has been
filed with the U.S. Securities and Exchange Commission (SEC) and
became effective on January 10, 2017. The offering is being made
only by means of a written prospectus and prospectus supplement
that will form a part of the registration statement. A preliminary
prospectus supplement and the accompanying prospectus relating to
the offering will be filed with the SEC and will be available on
the SEC’s website at www.sec.gov. Copies of the prospectus and
related preliminary prospectus supplement relating to the offering
may also be obtained, when available, by contacting Jefferies LLC,
by mail at Jefferies LLC Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by email at Prospectus_Department@Jefferies.com, or by telephone at
(877) 821-7388; or Cowen and Company, LLC, by mail at Cowen and
Company, LLC, c/o Broadridge Financial Services, 1155 Long Island
Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by
telephone at (631) 274-2806.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful, prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Codexis
Codexis is a leading protein engineering company that applies
its proprietary CodeEvolver® technology to develop proteins for a
variety of applications, including as biocatalysts for the
commercial manufacture of pharmaceuticals, fine chemicals and
industrial enzymes, and enzymes as biotherapeutics and for use in
molecular diagnostics. Codexis’ proven technology enables
improvements in protein performance meeting customer needs for
rapid, cost-effective and sustainable manufacturing in multiple
commercial scale implementations of biocatalytic processes.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Codexis, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor of the
Private Securities Litigation Reform Act of 1995, including
Codexis’ expected use of the proceeds of the proposed public
offering. Such forward-looking statements involve substantial risks
and uncertainties that could cause Codexis’ future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties related
to market conditions and the completion of the public offering on
the anticipated terms or at all. Codexis undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Codexis’ business in
general, please refer to Codexis’ prospectus supplement to be filed
with the SEC, including the documents incorporated by reference
therein, which include Codexis’ Annual Report on Form 10-K filed
with the SEC on March 15, 2018, and Codexis’ other periodic reports
filed with the SEC.
Codexis Contact: Gordon SangsterChief Financial
Officer(650) 421-8115gordon.sangster@codexis.com
Investor Relations Contact:LHA Jody Cain(310)
691-7100 jcain@lhai.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Apr 2023 to Apr 2024